Cardiovascular complications of selected antibodies used in oncological immunotherapy
Journal Title: OncoReview - Year 2017, Vol 7, Issue 2
Abstract
Immunotherapy supports other therapeutic methods and is an important element in the fight against cancer. Its main tasks include stimulation and guidance of the immune system to fight cancer, inhibition of the mechanisms that block the immune system, and direct destruction of neoplastic cells. Different from chemotherapy or hormonal therapy, its mechanism of action is associated with a different profile of adverse events. HER2 receptor inhibitors may cause symptoms of heart failure, which usually recede, once the treatment has been discontinued. Bevacizumab, an anti-VEGF antibody, induces numerous cardiovascular complications, including arterial hypertension, arterial embolism, haemorrhage and haemoptysis as well as venous thromboembolism.
Authors and Affiliations
Joanna Kufel-Grabowska
Keywords
Related Articles
- EP ID EP189007
- DOI 10.24292/01.OR.300617.4
- Views 232
- Downloads 0
Role of molecular examinations in qualification to first line treatment with erlotinib in NSCLC patients based on EURTAC study results
Between 2010–2011 the first EGFR thyrosine kinase inhibitor (EGFR TKI) – gefitinib, was registered in many countries in I line of treatment in patients with advanced and locally advanced non-small cell lung cancer (NSCLC...
Advanced or metastatic non-small-cell lung cancer treatment - new Polish goverment regulation
The article presents the non-small-cell lung cancer current treatment recommendations in consideration of Polish government regulation.
Perikardiocenteza i aspekty terapii doosierdziowej u chorych onkologicznych - opis przypadku
Przebieg procesu nowotworowego z towarzyszącym wysiękiem płynu do worka osierdziowego ma zmienną dynamikę, a obraz kliniczny i nasilenie objawów związane są bezpośrednio ze stopniem zaburzeń hemodynamicznych i szybkością...
Exemestan in breast cancer treatment
Hormonotherapy is one of the most important therapeutic options in the breast cancer treatment, either locally advanced or metastatic. Tamoxifen has been standard of care for many years, however new clinical trials resul...
Long-term survival of a young patient after multi-disciplinary treatment of initially inoperable stomach cancer with metastases to the liver and visceral lymph node
This paper reports on a 5-year survival of a 30-year-old male patient initially diagnosed with inoperable stomach cancer with metastases to the liver and the visceral lymph node. The systemic treatment regimen (8 cycles...